Curevac and GSK agree to resolve patent dispute litigation with Pfizer and BioNTech
08/08/2025 01:32
Aug 7 (Reuters) - Curevac 5CV.DE said on Thursday that the company and GSK GSK.L have entered an agreement to resolve patent dispute with Pfizer PFE.N and BioNTech 22UAy.DE over mRNA-based COVID-19 vaccines. (Reporting by Angela Christy in Bengaluru; Editing by Alan Barona) ((AngelaChristy.M@thomsonreuters.com))
Recent news on CureVac NV
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Biontech Closes Acquisition Of CureVac
Brief: BioNTech Says CureVac Shareholders Are Advised To Tender Their Shares By 6:00 P.M. Eastern Time On Tuesday, December 2, 2025
Brief: Curevac Reaffirms Its Expected Cash Runway Into 2028